Rasilez® (2008) (aliskiren hemifumarate) Tablets [Summary of Product Characteristics]. Novartis Pharmaceuticals, Basel
Wood JM, Maibaum J, Rahuel J, et al (2003) Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun 308:698–705
PubMed
Article
CAS
Google Scholar
Oh BH, Mitchell J, Herron JR, Chung J, Khan M, Keefe D (2007) Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. J Am Coll Cardiol 49:1157–1163
PubMed
Article
CAS
Google Scholar
Villamil A, Chrysant SG, Calhoun D et al (2007) Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens 25:217–226
PubMed
Article
CAS
Google Scholar
Kilo C, Taylor A, Tschoepe D, Ibram G, Fang H, Prescott MF (2007) Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. J Renin Angiotensin Aldosterone Syst 8:190–198
PubMed
Article
Google Scholar
Azizi M, Menard J, Bissery A, Guyene T, Bura-Riviere A (2007) Hormonal and hemodynamic effects of aliskiren and valsartan and their combination in sodium-replete normotensive individuals. Clin J Am Soc Nephrol 2:947–955
PubMed
Article
CAS
Google Scholar
Vaidyanathan S, Camenisch G, Schuetz H et al (2008) Pharmacokinetics of the oral direct renin inhibitor aliskiren in combination with digoxin, atorvastatin, and ketoconazole in healthy subjects: The role of P-glycoprotein in the disposition of aliskiren. J Clin Pharmacol 48:1323–1338
PubMed
Article
CAS
Google Scholar
Bailey DG (2010) Fruit juice inhibition of uptake transport: a new type of food–drug interaction. Br J Clin Pharmacol 70(5):645–655
PubMed
Article
CAS
Google Scholar
Becquemont L, Verstuyft C, Kerb R et al (2001) Effect of grapefruit juice on digoxin pharmacokinetics in humans. Clin Pharmacol Ther 70:311–316
PubMed
CAS
Google Scholar
Parker RB, Yates CR, Soberman JE, Laizure SC (2003) Effects of grapefruit juice on intestinal P-glycoprotein: evaluation using digoxin in humans. Pharmacotherapy 23:979–987
PubMed
Article
CAS
Google Scholar
Hanley MJ, Cancalon P, Widmer WW, Greenblatt DJ (2011) The effect of grapefruit juice on drug disposition. Expert Opin Drug Metab Toxicol 7(3):267–286
PubMed
Article
CAS
Google Scholar
Banfield C, Gupta S, Marino M, Lim J, Affrime M (2002) Grapefruit juice reduces the oral biavailability of fexofenadine but not desloratidine. Clin Pharmacokinetics 41:311–318
Article
CAS
Google Scholar
Dresser G, Kim R, Bailey DG (2005) Effect of grapefruit juice volume on the reduction of fexofenadine bioavailability: possible role of organic anion transporting polypeptides. Clin Pharmacol Ther 77:170–177
PubMed
Article
CAS
Google Scholar
Bailey DG, Dresser GK, Leake BF, Kim RB (2007) Narinjin is a major and selective clinical inhibitor of organic anion-transporting polypeptide 1A2 (OATP1A2) in grapefruit juice. Clin Pharmacol Ther 81:495–502
PubMed
Article
CAS
Google Scholar
Kullak-Ublick GA, Ismair MG, Stieger B, Landmann L, Huber R, Pizzagalli F, Fattinger K, Meier PJ, Hagenbuch B (2001) Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology 120(2):525–533
PubMed
Article
CAS
Google Scholar
Vavricka SR, Van Montfoort J, Ha HR, Meier PJ, Fattinger K (2002) Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver. Hepatology 36(1):164–172
PubMed
Article
CAS
Google Scholar
Groves CE, Evans KK, Dantzler WH, Wright SH (1994) Peritubular organic cation transport in isolated rabbit proximal tubules. Am J Physiol 266(3(2)):F450–F458
PubMed
CAS
Google Scholar
Vaidyanathan S, Jarugula V, Dieterich HA, Howard D, Dole WP (2008) Clinical pharmacokinetics and pharmacodynamics of aliskiren. Clin Pharmacokinet 47:515–531
PubMed
Article
CAS
Google Scholar
Tapaninen T, Neuvonen PJ, Niemi M (2010) Grapefruit juice greatly reduces the plasma concentrations of the OATP2B1 and CYP3A4 substrate aliskiren. Clin Pharm Ther 88:339–342
Article
CAS
Google Scholar
Tapaninen T, Neuvonen PJ, Niemi M (2011) Orange and apple juice greatly reduce the plasma concentrations of the OATP2B1 substrate aliskiren. Br J Clin Pharm 71:718–726
Article
CAS
Google Scholar
Dresser GK, Bailey DG, Leake BF et al (2002) Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clin Pharmacol Ther 71:11–20
PubMed
Article
CAS
Google Scholar
Allegra® package insert. Available at: http://www.rxlist.com/allegra-drug.htm
Tekturna® package insert. Available at: http://www.rxlist.com/tekturna-drug.htm
Feldman DL, Persohn E, Schutz H et al (2006) Renal localization of the renin inhibitor aliskiren (abst). J Clin Hypertens 8(Suppl A):A80
Google Scholar
Feldman DL, Jin L, Xuan H et al (2008) Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats. Hypertension 52:130–136
PubMed
Article
CAS
Google Scholar
Krop M, Garrelds IM, de Bruin RJ et al (2008) Aliskiren accumulates in renin secretory granules and binds plasma prorenin. Hypertension 52:1076–1083
PubMed
Article
CAS
Google Scholar
Sica D, Gradman A, Lederballe I, Meyers M et al (2006) Aliskiren, an oral renin inhibitor, provides long-term antihypertensive efficacy and safety in patients with hypertension. Eur Heart J 27(Suppl):P797
Google Scholar
Herron J, Mitchell J, Oh B et al (2006) The novel renin inhibitor aliskiren is not associated with rebound effects on blood pressure or plasma renin activity following treatment withdrawal (abst). J Clin Hypertens 8(Suppl A):A86
Google Scholar
Andersen K, Weinberger M, Constance C et al (2009) Comparative effects of aliskiren-based and ramipril-based therapy on the renin system during long-term (6 months) treatment and withdrawal in patients with hypertension. J Renin-Angiotensin-Aldosterone System 10(3):157–167
Article
CAS
Google Scholar